Seim Robin Gene 4
4 · OMNICELL, Inc · Filed Mar 12, 2019
Insider Transaction Report
Form 4
OMNICELL, IncOMCL
Seim Robin Gene
V.P., Finance & CFO
Transactions
- Exercise/Conversion
Common Stock
2019-03-11+28,800→ 93,418 total - Sale
Common Stock
2019-03-11$83.70/sh−7,296$610,667→ 86,122 total - Exercise/Conversion
Stock Options NQ (Right to Buy)
2019-03-11−13,849→ 0 totalExercise: $44.25From: 2019-02-06Exp: 2028-02-05→ Common Stock (13,849 underlying) - Exercise/Conversion
Stock Options NQ (Right to Buy)
2019-03-11−5,442→ 0 totalExercise: $27.70From: 2017-02-04Exp: 2027-02-03→ Common Stock (5,442 underlying) - Exercise/Conversion
Stock Options NQ (Right to Buy)
2019-03-11−7,165→ 0 totalExercise: $36.70From: 2018-02-08Exp: 2028-02-07→ Common Stock (7,165 underlying) - Exercise/Conversion
Stock Options NQ (Right to Buy)
2019-03-11−2,344→ 0 totalExercise: $34.02From: 2016-02-06Exp: 2025-02-06→ Common Stock (2,344 underlying) - Sale
Common Stock
2019-03-11$83.70/sh−21,504$1,799,861→ 64,618 total
Holdings
- 64,618
Common Stock
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan.
- [F2]The price reported in Column 4 is the average price of $83.6989. The sold price range between $82.05 to $83.35. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is the average price of $83.6989. The sold price range between $83.36 to $84.12. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.